Menu

Recipients of Experimental Herpes Vaccine File Lawsuit

The suit claims that Rational Vaccines, the company of recently deceased researcher William Halford, violated US and international laws when it carried out the procedure.

Mar 15, 2018
Catherine Offord

ISTOCK, BERNARDASVThree people who developed adverse side effects after receiving injections of an unapproved, experimental herpes vaccine have taken the matter to court, according to a lawsuit filed on Friday (March 9) in Illinois (via Kaiser Health News). Southern Illinois University researcher William Halford, who was responsible for the creation of the vaccine and the injections themselves, died last summer, but the recipients of his vaccine are claiming compensation from his company, Rational Vaccines, which they claim violated US and international laws that protect the rights of study participants.

“My clients are anxious to ensure such unethical experimentation on human subjects are not repeated,” Alan Milstein, a New Jersey lawyer who is representing the three participants, tells Kaiser Health News. The suit requests compensation for both the costs of medical care and for the “pain and suffering” and loss of dignity incurred by the participants.

Two of the procedures mentioned in the suit were carried out in 2016 as part of an unsanctioned trial in the Caribbean island nation St. Kitts and Nevis that included testing on 20 people. “The Ministry of Health states categorically that neither the Cabinet, the Ministry of Health, the office of Chief Medical Officer nor the St. Kitts and Nevis Medical Board has ever been approached on this project,” the country’s government noted afterwards (via Kaiser Health News). “By extension, none of these agencies has approved such a venture.”

The third procedure was performed in a hotel in Illinois, without the oversight of the US Food and Drug Administration (FDA). Kaiser Health News notes that Rational Vaccines, which Halford cofounded with filmmaker Agustín Fernández III in 2015, has not responded to request for comment on the most recent development, but has previously said it plans to continue testing the vaccine and working toward eventual FDA approval.

Meanwhile, Southern Illinois University is proceeding with a misconduct investigation relating to Halford’s research, and possible complicity among his colleagues.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!